CAR-T cell therapy involves engineering cancer patients’ own immune cells to recognize and attack cancer tumors. CAR-T therapy has great potential to improve patient-specific cancer therapy in a profound way. Numerous studies have implicated regulatory T cells as key mediators in the creation of an immunosuppressed microenvironment that enables tumors to escape attack by the host immune system. The Super CAR-T Cocktail therapy has shown promise in early human clinical trials for the treatment of blood cancer, renal, cervical and hepatic cancer.
“We are very impressed by the quality of the work done by Professor Shan and his team, and are excited by the safe and efficacious profile of this novel CAR-T cocktail therapy for cancerous diseases. This is the beginning of a long-term strategic partnership between IMUN and STCC. Together, we will expeditiously continue our quest in developing more affordable, safer, and more effective cancer immunotherapy programs,” said Noreen Griffin, Chief Executive Officer of Immune Therapeutics, Inc. Immune Therapeutics holds the patents to LDN and MENK.
"Chimeric antigen receptor (CAR) T-cell therapy has been effective in treating human B cell malignancies, as well as having potential in a multitude of other cancers. However, the persistence of CAR T cells after remission of the cancer leads to an eventual depletion of healthy B cells. Now, scientists have demonstrated a strategy to prevent this by coadministering an antibody after the tumor has gone.
Dirk Busch and his colleagues at the Technical University München published their results in The Journal of Clinical Investigation." - Oliver Worsley